What is Macrogenics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Macrogenics's interest expense for the
three
months ended in Dec. 2024 was $ 0.0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.1 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Macrogenics's Operating Income for the
three
months ended in Dec. 2024 was $ -52.8 Mil. Macrogenics's Interest Expense for the
three
months ended in Dec. 2024 was $ 0.0 Mil.
Macrogenics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Macrogenics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics (NAS:MGNX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Macrogenics's Interest Expense for the
three
months ended in Dec. 2024 was $0.0 Mil. Its
Operating Income
for the
three
months ended in Dec. 2024 was $-52.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2024 was $32.6 Mil.
Macrogenics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Macrogenics Business Description
Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Executives
| Jeffrey Stuart Peters |
officer: Acting General Counsel |
9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| James Karrels |
officer: SVP, CFO and Secretary |
9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Thomas Spitznagel |
officer: Sr VP, BPD & Manufacturing |
9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Eric Blasius Risser |
officer: Sr VP & Chief Business Officer |
9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Ezio Bonvini |
officer: Sr VP, Research & CSO |
9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Biotech Target N V |
10 percent owner |
ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
| Edward Hurwitz |
director |
|
| Margaret Liu |
director |
C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804 |
| Meenu Chhabra |
director |
C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
| William K Heiden |
director |
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| Biotech Ag Bb |
10 percent owner |
SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200 |
| Federica F. O'brien |
director |
C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
| Kenneth Galbraith |
director |
OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1 |
| Stephen L. Eck |
officer: Chief Medical Officer |
12212 TECHNOLOGY BLVD., AUSTIN TX 78727 |
| Matthew K Fust |
director |
C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MGNX has been successfully added to your 